MX359639B - Metodos y composiciones para uso en tratamientos celulares. - Google Patents
Metodos y composiciones para uso en tratamientos celulares.Info
- Publication number
- MX359639B MX359639B MX2012000396A MX2012000396A MX359639B MX 359639 B MX359639 B MX 359639B MX 2012000396 A MX2012000396 A MX 2012000396A MX 2012000396 A MX2012000396 A MX 2012000396A MX 359639 B MX359639 B MX 359639B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- cellular therapies
- therapies
- cellular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Abstract
La presente invención se refiere a un citoblasto de mesenquina para usar en el tratamiento, modulación, disminución y/o profilaxis de un trastorno inflamatorio y/o inmunitario en donde el citoblasto de mesénquima es administrble al sistema linfático por inyección intralinfática. Y una composición farmaceúticamente comprende al citoblasto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22427509P | 2009-07-09 | 2009-07-09 | |
PCT/IB2010/001968 WO2011004264A1 (en) | 2009-07-09 | 2010-07-09 | Methods and compositions for use in cellular therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012000396A MX2012000396A (es) | 2012-07-17 |
MX359639B true MX359639B (es) | 2018-10-04 |
Family
ID=42782196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000396A MX359639B (es) | 2009-07-09 | 2010-07-09 | Metodos y composiciones para uso en tratamientos celulares. |
Country Status (19)
Country | Link |
---|---|
US (1) | US8679834B2 (es) |
EP (2) | EP2451943B1 (es) |
JP (1) | JP5892931B2 (es) |
KR (1) | KR101788885B1 (es) |
CN (2) | CN107007626A (es) |
AU (1) | AU2010269962B2 (es) |
BR (1) | BR112012000534A2 (es) |
CA (1) | CA2767300C (es) |
DK (1) | DK2451943T3 (es) |
ES (1) | ES2479542T3 (es) |
HU (1) | HUE031921T2 (es) |
IL (1) | IL217377A (es) |
MX (1) | MX359639B (es) |
NZ (1) | NZ597975A (es) |
PL (1) | PL2451943T3 (es) |
PT (1) | PT2451943T (es) |
RU (1) | RU2610427C2 (es) |
SG (2) | SG10201403758SA (es) |
WO (1) | WO2011004264A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
SG165418A1 (en) | 2005-09-23 | 2010-10-28 | Cellerix Sl | Cell populations having immunoregulatory activity, method for isolation and uses |
WO2011006029A1 (en) | 2009-07-10 | 2011-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Artificial cell constructs for inducing immunological tolerance |
US11090363B2 (en) | 2009-07-10 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Vasoactive intestinal peptide release from microparticles |
EP2663316A2 (en) * | 2011-01-12 | 2013-11-20 | TiGenix, S.A.U. | Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases |
WO2013149211A2 (en) * | 2012-03-30 | 2013-10-03 | University Of Southern California | Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation |
US10258652B2 (en) | 2014-12-18 | 2019-04-16 | Pluristem Ltd. | Methods and compositions for treating and preventing muscle wasting disorders |
WO2016107563A1 (zh) * | 2014-12-29 | 2016-07-07 | 西比曼生物科技(上海)有限公司 | 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物 |
WO2016151476A1 (en) | 2015-03-23 | 2016-09-29 | Pluristem Ltd. | Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof |
WO2017141181A1 (en) | 2016-02-18 | 2017-08-24 | Pluristem Ltd. | Methods and compositions for treating cancers and neoplasms |
GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
WO2018211498A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with adipose-derived stem cells |
EP3624815A4 (en) | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
CN107349419A (zh) * | 2017-07-17 | 2017-11-17 | 广东颜值科技有限公司 | 一种细胞组合物及其制备方法和应用 |
CN107281469A (zh) * | 2017-07-17 | 2017-10-24 | 广东颜值科技有限公司 | 一种细胞组合物及其制备方法和应用 |
JPWO2020054829A1 (ja) * | 2018-09-14 | 2021-09-02 | ルカ・サイエンス株式会社 | ミトコンドリアのリンパ器官への移植およびそのための組成物 |
EP3941495A4 (en) * | 2019-03-19 | 2022-09-07 | Figene, LLC | TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE AND LUNG DEGENERATION USING ACTIVATED FIBROBLASTS AND EXOSOME DERIVATIVES THEREOF |
US11878037B2 (en) | 2019-05-31 | 2024-01-23 | Figene, Llc | Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis |
WO2021207192A1 (en) * | 2020-04-08 | 2021-10-14 | Figene, Llc | Methods and compositions for allergy and asthma treatment using fibroblasts |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2493081C (en) * | 2002-07-12 | 2013-04-23 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
BRPI0317064B8 (pt) * | 2002-12-06 | 2021-05-25 | Northwest Biotherapeutics Inc | composições compreendendo células dendríticas parcialmente amadurecidas in vitro |
SG165418A1 (en) | 2005-09-23 | 2010-10-28 | Cellerix Sl | Cell populations having immunoregulatory activity, method for isolation and uses |
US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
AU2008287063B2 (en) * | 2007-08-09 | 2013-10-24 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
JPWO2009031606A1 (ja) * | 2007-09-07 | 2010-12-16 | 日本ケミカルリサーチ株式会社 | 関節炎治療及び予防剤 |
EP2279246A4 (en) * | 2008-05-02 | 2012-03-28 | Massachusetts Inst Technology | METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE |
GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
-
2010
- 2010-07-09 CA CA2767300A patent/CA2767300C/en active Active
- 2010-07-09 ES ES10752171.8T patent/ES2479542T3/es active Active
- 2010-07-09 AU AU2010269962A patent/AU2010269962B2/en active Active
- 2010-07-09 CN CN201710067652.0A patent/CN107007626A/zh active Pending
- 2010-07-09 DK DK10752171.8T patent/DK2451943T3/en active
- 2010-07-09 EP EP10752171.8A patent/EP2451943B1/en active Active
- 2010-07-09 SG SG10201403758SA patent/SG10201403758SA/en unknown
- 2010-07-09 PT PT107521718T patent/PT2451943T/pt unknown
- 2010-07-09 PL PL10752171T patent/PL2451943T3/pl unknown
- 2010-07-09 US US13/382,426 patent/US8679834B2/en active Active
- 2010-07-09 NZ NZ597975A patent/NZ597975A/en unknown
- 2010-07-09 SG SG2012001574A patent/SG177582A1/en unknown
- 2010-07-09 BR BR112012000534A patent/BR112012000534A2/pt not_active Application Discontinuation
- 2010-07-09 CN CN2010800308900A patent/CN102549147A/zh active Pending
- 2010-07-09 EP EP16199980.0A patent/EP3150703A1/en not_active Withdrawn
- 2010-07-09 MX MX2012000396A patent/MX359639B/es active IP Right Grant
- 2010-07-09 JP JP2012519080A patent/JP5892931B2/ja active Active
- 2010-07-09 HU HUE10752171A patent/HUE031921T2/en unknown
- 2010-07-09 RU RU2012104529A patent/RU2610427C2/ru active
- 2010-07-09 KR KR1020127003364A patent/KR101788885B1/ko active IP Right Grant
- 2010-07-09 WO PCT/IB2010/001968 patent/WO2011004264A1/en active Application Filing
-
2012
- 2012-01-05 IL IL217377A patent/IL217377A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
PT2451943T (pt) | 2017-01-20 |
WO2011004264A1 (en) | 2011-01-13 |
PL2451943T3 (pl) | 2017-04-28 |
CN102549147A (zh) | 2012-07-04 |
EP2451943A1 (en) | 2012-05-16 |
CA2767300A1 (en) | 2011-01-13 |
IL217377A0 (en) | 2012-02-29 |
AU2010269962B2 (en) | 2016-04-14 |
US20120308585A1 (en) | 2012-12-06 |
KR101788885B1 (ko) | 2017-10-20 |
DK2451943T3 (en) | 2017-02-06 |
KR20120051006A (ko) | 2012-05-21 |
EP2451943B1 (en) | 2016-11-23 |
CN107007626A (zh) | 2017-08-04 |
SG177582A1 (en) | 2012-03-29 |
RU2012104529A (ru) | 2013-08-20 |
BR112012000534A2 (pt) | 2017-06-13 |
RU2610427C2 (ru) | 2017-02-10 |
ES2479542T3 (es) | 2017-05-26 |
NZ597975A (en) | 2014-06-27 |
HUE031921T2 (en) | 2017-08-28 |
CA2767300C (en) | 2020-01-07 |
IL217377A (en) | 2017-10-31 |
MX2012000396A (es) | 2012-07-17 |
JP5892931B2 (ja) | 2016-03-23 |
US8679834B2 (en) | 2014-03-25 |
ES2479542T1 (es) | 2014-08-20 |
SG10201403758SA (en) | 2014-10-30 |
EP3150703A1 (en) | 2017-04-05 |
JP2012532859A (ja) | 2012-12-20 |
AU2010269962A1 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
MX345909B (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan. | |
MX2013002048A (es) | Conjugados, particulas, composiciones y metodos relacionados. | |
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
WO2015002724A3 (en) | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | |
MY181898A (en) | Heterocyclic compounds and uses thereof | |
SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
MX2012007507A (es) | Compuestos de heteroarilo y usos de los mismos. | |
TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
MX2013012184A (es) | Composiciones formadoras de gel in situ. | |
MY161601A (en) | Films and compositions comprising the same | |
MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
MX2013002784A (es) | Heteroarilos fusionados y sus usos. | |
HK1142608A1 (en) | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5- | |
WO2012095743A3 (en) | Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases | |
PH12013502194A1 (en) | Antibodies to egfl7 and methods for their use | |
IN2012DN03404A (es) | ||
MX2012010127A (es) | Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos. | |
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |